Main Achievements / Principaux résultats

Pour consulter la liste exhaustive des publications de chaque équipe, voir les pages des différentes équipes.

2014 2013 2012 2011 2010 2009

2014

Lab

Collaborations

Trials Patents



Lab

Gut. 2014 Jul 22. pii: gutjnl-2014-307618 Intestinal steroidogenesis controls PPARγ expression in the colon and is impaired during UC. Bouguen G, Langlois A, Djouina M, Branche J, Koriche D, Dewaeles E, Mongy A, Auwerx J, Colombel JF, Desreumaux P, Dubuquoy L, Bertin B.

Am J Clin Nutr. 2014 Sep;100(3):850-8.Growth hormone enhances fat-free mass and glutamine availability in patients with short-bowel syndrome: an ancillary double-blind, randomized crossover study. Seguy D, Darmaun D, Duhamel A, Thuillier F, Cynober L, Cortot A, Gottrand F, Messing B.

Hepatology. 2014 Apr;59(4):1471-81 Hepatocellular carcinoma screening in patients with compensated hepatitis C virus (HCV)-related cirrhosis aware of their HCV status improves survival: a modeling approach. Mourad A, Deuffic-Burban S, Ganne-Carrié N, Renaut-Vantroys T, Rosa I, Bouvier AM, Launoy G, Cattan S, Louvet A, Dharancy S, Trinchet JC, Yazdanpanah Y, Mathurin P.

J Hepatol. 2014 Jul;61(1):7-14 Should we await IFN-free regimens to treat HCV genotype 1 treatment-naive patients? A cost-effectiveness analysis (ANRS 95141). Deuffic-Burban S, Schwarzinger M, Obach D, Mallet V, Pol S, Pageaux GP, Canva V, Deltenre P, Roudot-Thoraval F, Larrey D, Dhumeaux D, Mathurin P, Yazdanpanah Y.



Collaborations

J Hepatol. 2014 Oct;61(4):891-902 Homozygous MTTP and APOB mutations may lead to hepatic steatosis and fibrosis despite metabolic differences in congenital hypocholesterolemia. Di Filippo M, Moulin P, Roy P, Samson-Bouma ME, Collardeau-Frachon S, Chebel-Dumont S, Peretti N, Dumortier J, Zoulim F, Fontanges T, Parini R, Rigoldi M, Furlan F, Mancini G, Bonnefont-Rousselot D, Bruckert E, Schmitz J, Scoazec JY, Charrière S, Villar-Fimbel S, Gottrand F, Dubern B, Doummar D, Joly F, Liard-Meillon ME, Lachaux A, Sassolas A.




haut de la page


2013

Lab

Collaborations

Trials Patents



Lab

J Hepatol. 2013 Dec;59(6):1346-8 Mathematical modeling: a tool for selecting agents with complementary modes of action? Deuffic-Burban S, Yazdanpanah Y.

 


Collaborations

N Engl J Med. 2013 Aug 22;369(8):711-21 Vedolizumab as induction and maintenance therapy for Crohn’s disease. Sandborn WJ, Feagan BG, Rutgeerts P, Hanauer S, Colombel JF, Sands BE, Lukas M, Fedorak RN, Lee S, Bressler B, Fox I, Rosario M, Sankoh S, Xu J, Stephens K, Milch C, Parikh A; GEMINI 2 Study Group.

N Engl J Med. 2013 Aug 22;369(8):699-710 Vedolizumab as induction and maintenance therapy for ulcerative colitis. Feagan BG, Rutgeerts P, Sands BE, Hanauer S, Colombel JF, Sandborn WJ, Van Assche G, Axler J, Kim HJ, Danese S, Fox I, Milch C, Sankoh S, Wyant T, Xu J, Parikh A; GEMINI 1 Study Group.

J Hepatol. 2013 Jun;58(6):1209-17. Improving outcomes of biliary atresia: French national series 1986-2009. Chardot C, Buet C, Serinet MO, Golmard JL, Lachaux A, Roquelaure B, Gottrand F, Broué P, Dabadie A, Gauthier F, Jacquemin E.

Nat Genet. 2013 Jan;45(1):76-82 New loci associated with birth weight identify genetic links between intrauterine growth and adult height and metabolism. Horikoshi M et al.



haut de la page


2012

Predicted Effects of Treatment for HCV Infection Vary Among European Countries
Deuffic-Burban S, Deltenre P, Buti M, Stroffolini T, Parkes J, Mühlberger N, Siebert U, Moreno C, Hatzakis A, Rosenberg W, Zeuzem S, Mathurin P
Gastroenterology. 2012 Aug 2

Safety and Efficacy of Antigen-Specific Regulatory T-Cell Therapy for Patients With Refractory Crohn’s Disease
Desreumaux P, Foussat A, Allez M, Beaugerie L, Hébuterne X, Bouhnik Y, Nachury M, Brun V, Bastian H, Belmonte N, Ticchioni M, Duchange A, Morel-Mandrino P, Neveu V, Clerget-Chossat N, Forte M, Colombel JF
Gastroenterology. 2012 Aug 8. pii: S0016-5085(12)01159-6. doi: 10.1053/j.gastro.2012.07.116.


haut de la page

2011



Early liver transplantation for severe alcoholic hepatitis
Mathurin P, Moreno C, Samuel D, Dumortier J, Salleron J, Durand F, Castel H, Duhamel A, Pageaux GP, Leroy V, Dharancy S, Louvet A, Boleslawski E, Lucidi V, Gustot T, Francoz C, Letoublon C, Castaing D, Belghiti J, Donckier V, Pruvot FR, Duclos-Vallée JC

N Engl J Med. 2011 Nov 10;365(19):1790-800

Mesenteric fat as a source of C reactive protein and as a target for bacterial translocation in Crohn’s disease
Peyrin-Biroulet L, Gonzalez F, Dubuquoy L, Rousseaux C, Dubuquoy C, Decourcelle C, Saudemont A, Tachon M, Béclin E, Odou MF, Neut C, Colombel JF, Desreumaux P
Gut. 2011 Sep 21

Impact of hepatitis C triple therapy availability upon the number of patients to be treated and associated costs in France: a model-based analysis.
Deuffic-Burban S, Mathurin P, Pol S, Larsen C, Roudot-Thoraval F, Desenclos JC, Dhumeaux D, Yazdanpanah Y

Gut 2011 Sep 19

H1N1 vaccines in a large observational cohort of patients with inflammatory bowel disease treated with immunomodulators and biological therapy
Rahier JF, Papay P, Salleron J, Sebastian S, Marzo M, Peyrin-Biroulet L, Garcia-Sanchez V, Fries W, van Asseldonk DP, Farkas K, de Boer NK, Sipponen T, Ellul P, Louis E, Peake ST, Kopylov U, Maul J, Makhoul B, Fiorino G, Yazdanpanah Y, Chaparro M; for the European Crohn’s and Colitis Organisation (ECCO)
Gut 2011


haut de la page

2010

Infliximab, azathioprine, or combination therapy for Crohn’s disease
Colombel JF, Sandborn WJ, Reinisch W, Mantzaris GJ, Kornbluth A, Rachmilewitz D, Lichtiger S, D’Haens G, Diamond RH, Broussard DL, Tang KL, van der Woude CJ, Rutgeerts P; SONIC Study Group
N Engl J Med. 2010 ; 362(15):1383-95

Human eosinophils exert TNF-α and granzyme A-mediated tumoricidal activity toward colon carcinoma cells
Legrand F, Driss V, Delbeke M, Loiseau S, Hermann E, Dombrowicz D, Capron M
J Immunol. 2010; 185(12):7443-51

Breast-feeding modulates the influence of the peroxisome proliferator-activated receptor-gamma (PPARG2) Pro12Ala polymorphism on adiposity in adolescents: The Healthy Lifestyle in Europe by Nutrition in Adolescence (HELENA) cross-sectional study
Verier C, Meirhaeghe A, Bokor S, Breidenassel C, Manios Y, Molnár D, Artero EG, Nova E, De Henauw S, Moreno LA, Amouyel P, Labayen I, Bevilacqua N, Turck D, Béghin L, Dallongeville J, Gottrand F; Healthy Lifestyle in Europe by Nutrition in Adolescence (HELENA) Study Group
Diabetes Care 2010 ; 33(1):190-6

Neutrophil migration during liver injury is under nucleotide-binding oligomerization domain 1 control
Dharancy S, Body-Malapel M, Louvet A, Berrebi D, Gantier E, Gosset P, Viala J, Hollebecque A, Moreno C, Philpott DJ, Girardin SE, Sansonetti PJ, Desreumaux P, Mathurin P, Dubuquoy L
Gastroenterology 2010 ; 138(4):1546-56

Peroxisome proliferator-activated receptor gamma activation is required for maintenance of innate antimicrobial immunity in the colon
Peyrin-Biroulet L, Beisner J, Wang G, Nuding S, Oommen ST, Kelly D, Parmentier-Decrucq E, Dessein R, Merour E, Chavatte P, Grandjean T, Bressenot A, Desreumaux P, Colombel JF, Desvergne B, Stange EF, Wehkamp J, Chamaillard M
Proc Natl Acad Sci U S A. 2010 ; 107(19):8772-7


haut de la page

2009

Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study
Beaugerie L, Brousse N, Bouvier AM, Colombel JF, Lémann M, Cosnes J, Hébuterne X, Cortot A, Bouhnik Y, Gendre JP, Simon T, Maynadié M, Hermine O, Faivre J, Carrat F; CESAME Study Group
Lancet 2009 ; 374(9701):1617-25

The European (ECCO) Consensus on infection in IBD: what does it change for the clinician?
Rahier JF, Yazdanpanah Y, Colombel JF, Travis S
Gut 2009 ; 58(10):1313-5

Colectomy rate comparison after treatment of ulcerative colitis with placebo or infliximab
Sandborn WJ, Rutgeerts P, Feagan BG, Reinisch W, Olson A, Johanns J, Lu J, Horgan K, Rachmilewitz D, Hanauer SB, Lichtenstein GR, de Villiers WJ, Present D, Sands BE, Colombel JF
Gastroenterology 2009 ; 137(4):1250-60

TLR2-dependent eosinophil interactions with mycobacteria: role of alpha-defensins
Driss V, Legrand F, Hermann E, Loiseau S, Guerardel Y, Kremer L, Adam E, Woerly G, Dombrowicz D, Capron M
Blood 2009 ; 113(14):3235-44

Adalimumab for the treatment of fistulas in patients with Crohn’s disease
Colombel JF, Schwartz DA, Sandborn WJ, Kamm MA, D’Haens G, Rutgeerts P, Enns R, Panaccione R, Schreiber S, Li J, Kent JD, Lomax KG, Pollack PF
Gut 2009 ; 58(7):940-8


haut de la page


Lab

Collaborations

Trials Patents



Lab

Gut. 2014 Jul 22. pii: gutjnl-2014-307618 Intestinal steroidogenesis controls PPARγ expression in the colon and is impaired during UC. Bouguen G, Langlois A, Djouina M, Branche J, Koriche D, Dewaeles E, Mongy A, Auwerx J, Colombel JF, Desreumaux P, Dubuquoy L, Bertin B.

Am J Clin Nutr. 2014 Sep;100(3):850-8.Growth hormone enhances fat-free mass and glutamine availability in patients with short-bowel syndrome: an ancillary double-blind, randomized crossover study. Seguy D, Darmaun D, Duhamel A, Thuillier F, Cynober L, Cortot A, Gottrand F, Messing B.

Hepatology. 2014 Apr;59(4):1471-81 Hepatocellular carcinoma screening in patients with compensated hepatitis C virus (HCV)-related cirrhosis aware of their HCV status improves survival: a modeling approach. Mourad A, Deuffic-Burban S, Ganne-Carrié N, Renaut-Vantroys T, Rosa I, Bouvier AM, Launoy G, Cattan S, Louvet A, Dharancy S, Trinchet JC, Yazdanpanah Y, Mathurin P.

J Hepatol. 2014 Jul;61(1):7-14 Should we await IFN-free regimens to treat HCV genotype 1 treatment-naive patients? A cost-effectiveness analysis (ANRS 95141). Deuffic-Burban S, Schwarzinger M, Obach D, Mallet V, Pol S, Pageaux GP, Canva V, Deltenre P, Roudot-Thoraval F, Larrey D, Dhumeaux D, Mathurin P, Yazdanpanah Y.



Collaborations



Trials



Patents